News

Rhythm Seeks to Test Setmelanotide in More Obesity Disorders This Year

Rhythm Pharmaceuticals has identified 31 additional genes whose mutations may be amenable to setmelanotide, its U.S.-approved therapy for genetic obesity disorders linked to the melanocortin-4 receptor (MC4R) pathway. This discovery is the result of Rhythm’s sequencing efforts and precision approach that has been recently validated in a Phase…

FDA-approved Setmelanotide Shows Promise in More Genetic Obesity Disorders

Three months of treatment with setmelanotide, an approved therapy for genetic obesity disorders, led to clinically meaningful body weight loss in adolescents and adults with additional diseases linked to the melanocortin-4 receptor (MC4R) pathway, data show. These interim data, from a Phase 2 basket trial, highlight setmelanotide’s potential…

NORD’s Caregiver Respite Program Continues Through Pandemic

Caring for a loved one with a rare disease, especially during these uncertain times, demands significant time, attention, patience, and dedication. To help meet that need, the National Organization for Rare Disorders (NORD)’s Rare Caregiver Respite Program may be a helpful resource. The program seeks to give a…

Recent Posts